Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ACBP monoclonal antibody
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
The anti-ACBP monoclonal antibody is a research-stage biologic designed to neutralize extracellular Acyl-CoA Binding Protein (ACBP), also known as Diazepam Binding Inhibitor (DBI). ACBP is a phylogenetically conserved protein that, when secreted, acts as a hunger signal and a negative regulator of autophagy. In preclinical studies, this neutralizing antibody has demonstrated hepatoprotective effects in murine models of liver ischemia/reperfusion injury, acetaminophen toxicity, and nonalcoholic steatohepatitis (NASH) by inducing autophagy and reducing inflammation and fibrosis. In the context of B-cell lymphoma, ACBP is implicated in glucocorticoid resistance and immune evasion; the antibody aims to restore dendritic cell antigen presentation and enhance antitumor immunity by blocking the ACBP-GABA_A receptor-TSC22D3 axis.
- Other names
- anti-diazepam binding inhibitor monoclonal antibodyanti-DBI monoclonal antibody
02
Targets
ACBP (Acyl-CoA-binding protein)
Beyond the preview
Go deeper on anti-ACBP monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ACBP monoclonal antibody.